This company listing is no longer active
Global Blood Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Anahtar bilgiler
66.2%
Kazanç büyüme oranı
65.8%
EPS büyüme oranı
Biotechs kazanç büyümesi | 35.6% |
Gelir büyüme oranı | 32.5% |
Gelecekteki özkaynak getirisi | -88.3% |
Analist kapsamı | Good |
Son güncelleme | n/a |
Gelecekteki son büyüme güncellemeleri
Recent updates
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2024 | 627 | -71 | -11 | 29 | 14 |
12/31/2023 | 439 | -191 | -230 | -124 | 18 |
12/31/2022 | 282 | -306 | -224 | -244 | 18 |
6/30/2022 | 235 | -322 | -251 | -249 | N/A |
3/31/2022 | 211 | -310 | -252 | -249 | N/A |
12/31/2021 | 195 | -303 | -260 | -257 | N/A |
9/30/2021 | 180 | -277 | -241 | -234 | N/A |
6/30/2021 | 165 | -266 | -216 | -209 | N/A |
3/31/2021 | 149 | -249 | -220 | -212 | N/A |
12/31/2020 | 124 | -248 | -221 | -212 | N/A |
9/30/2020 | 85 | -282 | -236 | -229 | N/A |
6/30/2020 | 48 | -286 | -249 | -242 | N/A |
3/31/2020 | 16 | -291 | -239 | -233 | N/A |
12/31/2019 | 2 | -267 | -198 | -194 | N/A |
9/30/2019 | N/A | -220 | -167 | -166 | N/A |
6/30/2019 | N/A | -199 | -145 | -143 | N/A |
3/31/2019 | N/A | -182 | -143 | -139 | N/A |
12/31/2018 | N/A | -174 | -140 | -135 | N/A |
9/30/2018 | N/A | -166 | -133 | -127 | N/A |
6/30/2018 | N/A | -152 | -128 | -122 | N/A |
3/31/2018 | N/A | -135 | -111 | -107 | N/A |
12/31/2017 | N/A | -117 | -96 | -93 | N/A |
9/30/2017 | N/A | -103 | -90 | -88 | N/A |
6/30/2017 | N/A | -95 | -82 | -81 | N/A |
3/31/2017 | N/A | -89 | -77 | -76 | N/A |
12/31/2016 | N/A | -82 | -69 | -68 | N/A |
9/30/2016 | N/A | -71 | -59 | -57 | N/A |
6/30/2016 | N/A | -65 | -49 | -47 | N/A |
3/31/2016 | N/A | -58 | N/A | -39 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: G5B is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).
Kazançlar ve Piyasa: G5B is forecast to become profitable over the next 3 years, which is considered above average market growth.
Yüksek Büyüme Kazançları: G5B is expected to become profitable in the next 3 years.
Gelir ve Pazar: G5B's revenue (32.5% per year) is forecast to grow faster than the German market (3.9% per year).
Yüksek Büyüme Geliri: G5B's revenue (32.5% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: G5B is forecast to be unprofitable in 3 years.